Clinical Trial Update: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing chidamide+syntilimab+bevacizumab versus standard second-line FOLFIRI+bevacizumab in metastatic microsatellite-stable colorectal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Microsatellite-stable Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Chidamide (chidamide)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• syntilimab (syntilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Microsatellite-stable Colorectal Cancer | Phase 3 | Status: RECRUITING